Elon Musk’s ally Jared Isaacman just lit the fuse on something much bigger than a moon landing. Speaking on CNBC, the newly confirmed NASA Administrator said theElon Musk’s ally Jared Isaacman just lit the fuse on something much bigger than a moon landing. Speaking on CNBC, the newly confirmed NASA Administrator said the

Elon Musk's Jared Isaacman say his NASA push for space data centers will unlock 'orbital economy'

2025/12/27 09:30
3 min read

Elon Musk’s ally Jared Isaacman just lit the fuse on something much bigger than a moon landing. Speaking on CNBC, the newly confirmed NASA Administrator said the United States will head back to the moon under President Donald Trump’s second term.

And this time, it’s for what Jared calls the “orbital economy.” “We want to have that opportunity to explore and realize the scientific, economic and national security potential on the moon,” Jared said during the interview.

He pointed directly to Trump’s renewed interest in space, calling it the key to turning the moon into an off-Earth economic hub.

The US Senate had finally confirmed Jared’s appointment last week after a chaotic back-and-forth that dragged all through 2025.

Trump’s NASA pick returns with space business agenda

Trump first picked Jared to run NASA back in December 2024. Then, in May, he suddenly yanked the nomination. No reason was given, but insiders allegedly pointed fingers at Jared’s tight relationship with Elon, since Trump and the latter publicly broke up last summer.

But the beef didn’t last. Trump circled back in November and renominated Jared, who already had the astronaut badge after flying on SpaceX’s Crew Dragon in 2021.

Now he’s not just aiming for the moon.Jared laid out plans for space data centers, nuclear power, and Helium-3 mining.

The rare gas could be a future fuel for fusion reactors and is buried in the moon’s surface. He also wants a permanent base, with nuclear propulsion systems ready to go beyond the moon.

That’s not a fantasy. Jared made it clear that these ideas are already in motion. NASA is working with SpaceX, Jeff Bezos’ Blue Origin, and Boeing under the Artemis campaign, which focuses on building a long-term presence on the moon and preparing for missions to Mars.

Trump’s One Big Beautiful Bill Act gave this campaign a huge boost by dropping $9.9 billion into NASA’s pocket earlier this year. Artemis II, the first crewed test flight on NASA’s Space Launch System and Orion spacecraft, is scheduled soon. That mission will be followed by Artemis III, with SpaceX providing the lunar landing vehicle.

Jared also said both SpaceX and Blue Origin are making reusable heavy-lift rockets using on-orbit cryogenic propellant transfer. He said, “That’s what’s going to enable us to be able to go to and from the moon affordably, with great frequency, and set up for missions to Mars and beyond.”

Tesla’s Cybertruck problem gets a SpaceX-sized bailout

Back on Earth, Tesla’s numbers are looking ugly. The company is struggling to sell even 20,000 Cybertrucks a year. That’s a far cry from Elon’s original promise of 500,000 units. Warehouses are now overflowing with unsold trucks. Production has already been scaled back.

But here comes SpaceX. The company bought over 1,000 Cybertrucks, and they might double that soon. An X user posted a video showing a storage lot filled with the vehicles. With each truck priced around $80,000, SpaceX’s order could total between $80 million and $160 million in Tesla sales.

Clearly, SpaceX is now turning into the main source of Elon’s wealth, not Tesla, like we’re used to. If things keep going this way, it will almost certainly even push his net worth over $1 trillion by this time next year.

Get up to $30,050 in trading rewards when you join Bybit today

Market Opportunity
Dogelon Mars Logo
Dogelon Mars Price(ELON)
$0.00000003291
$0.00000003291$0.00000003291
-1.23%
USD
Dogelon Mars (ELON) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26